The Atopic Dermatitis and Novel Agents Comparative ... in serious infection risk was observed in the comparison of tralokinumab and dupilumab (RR, 0.83; 95% CI, 0.29-2.35). The JAK inhibitor ...

A prospective registry study found a greater risk for infections associated with JAK inhibitors in adolescents and adults with moderate to severe atopic dermatitis compared with biologics.

The EMA has started a review of Leo Pharma’s interleukin-13 inhibitor tralokinumab as an antibody therapy for atopic dermatitis, a category that is currently dominated by Sanofi and Regeneron ...

Once you have established atopic dermatitis, often ... at least 2 biologic therapies that have been studied, dupilumab and tralokinumab. Whether it be topical or systemic therapy, if you get ...

Tralokinumab is approved for the treatment of adults with moderate-to-severe atopic dermatitis in the EU, UK, Canada, United Arab Emirates, and Switzerland. It is also approved for adults in the ...

Approved, these latter few I've mentioned, dupilumab down to six months of age, tralokinumab ... a once a day pill for moderate to severe atopic dermatitis down to 12 years of age, and abrocitinib ...

Janus kinase (JAK) inhibitors, including ruxolitinib cream and abrocitinib, demonstrate strong efficacy in atopic dermatitis ...

Atopic dermatitis is the most common form of eczema ... biologics such as Dupixent (dupilumab) and Adbry (tralokinumab-ldrm), or Janus kinase (JAK) inhibitors including Cibinqo (abrocitinib ...

Atopic dermatitis is an allergy affecting approximately 10% of the Japanese population, with symptoms closely related to ...

In this video, Peter Lio, MD, discussed updates on topical agents, biologics and drugs in the pipeline in atopic dermatitis from presentations at the American Academy of Dermatology meeting.

Atopic dermatitis highlights from AAD 2025 include phase 3 trial results on rocatinlimab and delgocitinib, findings on tapinarof 1% cream, and early dosing data on a new JAK1/TYK2 inhibitor.